To Book an Appointment

ABO-Incompatible Kidney Transplant: Advances & Outcomes

By Dr. Amit Goel in Urology , Kidney Transplant , Robotic Surgery

Dec 31 , 2025 | 2 min read

For decades, blood group incompatibility between donor and recipient was considered an absolute contraindication to kidney transplantation. This was due to the risk that a recipient’s pre-formed anti-ABO antibodies would immediately attack the donor kidney’s blood group antigens, causing hyperacute rejection and graft loss. However, advances in immunology, desensitisation techniques, and clinical protocols have dramatically changed this outlook.

Why Blood Group Mismatch Was a Problem

The ABO blood group system determines the presence of A and B antigens on red blood cells and critically, on the endothelial cells lining blood vessels in transplanted organs as well. When a recipient has naturally occurring antibodies against a donor’s ABO antigens (for example, a blood type O recipient receiving a type A kidney), these antibodies can bind to the graft and trigger immediate and catastrophic immune injury. Historically, this made ABO-incompatible (ABOi) transplants rare and high-risk.

Modern Breakthroughs in Transplant Medicine

Recent decades have brought major advances that allow successful kidney transplants despite ABO mismatch:

Desensitisation and Antibody Removal

Modern protocols use therapies such as:
Plasmapheresis or immunoadsorption to remove anti-ABO antibodies from the recipient’s blood.
Targeted immunosuppression with agents like rituximab (anti-CD20 antibody) to reduce the production of these antibodies.

These approaches help reduce antibody levels before transplant and prevent early antibody-mediated rejection.

Accommodation

Even after transplantation, some grafts develop a state where they resist antibody-mediated injury despite the presence of circulating antibodies. This phenomenon, known as accommodation, helps explain why many ABOi grafts can survive and function long-term.

Improved Outcomes With Long-Term Data

Multiple studies and meta-analyses now show that outcomes after ABO-incompatible transplant can be similar to ABO-compatible transplants, especially when modern desensitisation and immunosuppressive regimens are used. Long-term follow-up cohorts report high patient and graft survival rates, with acceptable rates of complications such as antibody-mediated rejection.

Clinical Practice: What This Means Today

Expanded Donor Pool: Patients with willing donors who are blood group mismatched no longer have to wait months or years for a compatible match. ABOi transplantation increases the number of usable living donors.
Alternative to Paired Exchange: In settings where paired kidney donation isn’t feasible, direct ABOi transplants provide an important alternative.
Tailored Protocols: Individualised desensitisation strategies based on antibody titres and detailed immunological profiling help optimise outcomes.

Conclusion

The historical view of blood group incompatibility as a strict barrier to kidney transplantation has been overturned by modern medicine. With advanced desensitisation protocols, better immunosuppression, and long-term clinical validation, ABO-incompatible kidney transplants have become safe and effective options, expanding donor availability and saving lives previously lost on transplant waiting lists.

Written and Verified by: